Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 5/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 5/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 4/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8281116 | 0.79 | PTPN1 (0.62) | MEN1KMT2AALDH1A1PTPN1PTPN5 | |
| SCHEMBL712861 | 0.78 | L3MBTL1 (0.47) | L3MBTL1GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL14018611 | 0.76 | HSD17B1 (0.62) | HSD17B1HSD17B2NR1H3CYP11B1CYP11B2 | |
| SCHEMBL3461784 | 0.74 | HSD17B1 (0.59) | HSD17B1HSD17B2NR1H3CYP11B1CYP11B2 | |
| SCHEMBL3462121 | 0.73 | HSD17B1 (0.56) | HSD17B1HSD17B2NR1H3CYP11B1CYP11B2 | |
| SCHEMBL8280448 | 0.72 | MAPT (0.64) | LMNAPOLBHTTPTPN1PTPN5 | |
| SCHEMBL3461368 | 0.71 | HSD17B1 (0.54) | GAAMEN1KMT2AHSD17B1HSD17B2 | |
| SCHEMBL4183469 | 0.71 | HSD17B1 (0.57) | MEN1KMT2AHSD17B1HSD17B2NR1H3 | |
| SCHEMBL27633575 | 0.70 | MEN1 (0.50) | L3MBTL1GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL1634416 | 0.69 | L3MBTL1 (1.00) | L3MBTL1GAAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120052057-A9 | METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS | BIOTIE THERAPIES CORPORATION (FI) | 2012-03-01 | — | — | US | claimed |
| US-20110150859-A1 | METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS | BIOTIE THERAPIES CORPORATION (FI) | 2011-06-23 | — | — | US | claimed |
| EP-2140029-A2 | A METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS | Biotie Therapies Corp. (FI) | 2010-01-06 | — | — | EP | claimed |
| WO-2008125738-A2 | A METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-23 | — | — | WO | claimed |
| US-20120052057-A9 | METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS | BIOTIE THERAPIES CORPORATION (FI) | 2012-03-01 | — | — | US | disclosed |
| US-20110150859-A1 | METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS | BIOTIE THERAPIES CORPORATION (FI) | 2011-06-23 | — | — | US | disclosed |
| EP-2140029-A2 | A METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS | Biotie Therapies Corp. (FI) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008125738-A2 | A METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-23 | — | — | WO | disclosed |
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| WO-2005090298-A1 | SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | NR1I2, ITGA2, ITGB2 | L3MBTL1 4578/4885GAA 4655/4885MEN1 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.